Walleye Capital LLC Grows Position in Bruker Corporation $BRKR

Walleye Capital LLC grew its holdings in shares of Bruker Corporation (NASDAQ:BRKR) by 6,405.1% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 14,116 shares of the medical research company’s stock after purchasing an additional 13,899 shares during the quarter. Walleye Capital LLC’s holdings in Bruker were worth $510,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Orbis Allan Gray Ltd bought a new stake in shares of Bruker in the second quarter valued at approximately $192,735,000. Price T Rowe Associates Inc. MD grew its stake in Bruker by 2,963.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,366,520 shares of the medical research company’s stock valued at $111,488,000 after buying an additional 2,289,269 shares in the last quarter. AQR Capital Management LLC grew its stake in Bruker by 125.3% in the 2nd quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company’s stock valued at $137,065,000 after buying an additional 1,850,215 shares in the last quarter. Franklin Resources Inc. raised its holdings in Bruker by 317.7% during the 4th quarter. Franklin Resources Inc. now owns 2,309,404 shares of the medical research company’s stock valued at $108,796,000 after acquiring an additional 1,756,460 shares during the period. Finally, Millennium Management LLC raised its holdings in Bruker by 222.6% during the 4th quarter. Millennium Management LLC now owns 1,839,587 shares of the medical research company’s stock valued at $86,663,000 after acquiring an additional 1,269,316 shares during the period. Hedge funds and other institutional investors own 79.52% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently commented on BRKR. Wolfe Research started coverage on Bruker in a report on Monday, June 1st. They issued a “peer perform” rating for the company. Leerink Partners boosted their price objective on Bruker from $60.00 to $70.00 and gave the company an “outperform” rating in a research note on Tuesday, July 7th. Wall Street Zen raised Bruker from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Guggenheim raised their target price on Bruker from $50.00 to $70.00 and gave the stock a “buy” rating in a research note on Monday, June 29th. Finally, Stifel Nicolaus set a $45.00 target price on Bruker in a report on Friday, May 8th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $56.79.

Bruker Stock Down 2.7%

Shares of NASDAQ:BRKR opened at $60.45 on Friday. The firm has a fifty day moving average price of $56.32 and a two-hundred day moving average price of $46.32. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.55 and a quick ratio of 0.72. Bruker Corporation has a one year low of $28.53 and a one year high of $64.54. The company has a market cap of $9.20 billion, a price-to-earnings ratio of -251.88, a PEG ratio of 1.99 and a beta of 1.29.

Bruker (NASDAQ:BRKR) last announced its earnings results on Wednesday, May 6th. The medical research company reported $0.31 earnings per share for the quarter, beating analysts’ consensus estimates of $0.23 by $0.08. Bruker had a negative net margin of 0.65% and a positive return on equity of 11.60%. The business had revenue of $823.40 million for the quarter, compared to the consensus estimate of $795.62 million. During the same period last year, the firm posted $0.47 earnings per share. Bruker’s quarterly revenue was up 2.7% on a year-over-year basis. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Analysts anticipate that Bruker Corporation will post 2.12 EPS for the current fiscal year.

Bruker Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, July 7th. Stockholders of record on Monday, June 22nd were given a dividend of $0.05 per share. The ex-dividend date was Monday, June 22nd. This represents a $0.20 annualized dividend and a dividend yield of 0.3%. Bruker’s dividend payout ratio (DPR) is -83.33%.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.